title: Augmentative effects of phytohemagglutinin-P on proliferation and cytotoxicity of interleukin-2-activated canine peripheral blood lymphocytes.
abstract: Canine peripheral blood lymphocytes (PBL) were simulated with recombinant human interleukin-2 (rhIL-2) alone, or with phytohemagglutinin-P (PHA) and subsequent rhIL-2 in order to obtain large numbers of lymphokine-activated killer (LAK) cells. Incubation of PBL with rhIL-2 alone allowed proliferation of large granular lymphocyte (LGL)-like lymphocytes, and the cytotoxic activity of the lymphocytes against canine transmissible venereal sarcoma cells was detected 5-7 days after the culture onset. However, the lymphocytes died within 2 weeks of culture, resulting in limited generation of functional LAK cells. Thus, PBL pretreated with PHA are subjected to rhIL-2-dependent culture. Small- or middle-sized lymphocytes predominantly proliferated in response to rhIL-2, and proliferation of the lymphocytes was sustained for longer than 30 days by repeated stimulations with PHA and subsequent rhIL-2. Cytotoxicity reached significant levels from 2 weeks after the culture onset and thereafter remained almost constant for at least 2 weeks, leading to large-scale production of the LAK cells. Pretreatment of PBL and PHA seems to enhance the LAK cell functions through modification of the precursors of the effector LAK cells.
authors.affiliation: Institute of Experimental Animal Sciences, Osaka University Medical School, Suita, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mizuno
authors.forename: T
authors.initials: T
authors.lastname: Fujinaga
authors.forename: T
authors.initials: T
authors.lastname: Kurosawa
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004285:Dogs; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology* / Q000502:physiology; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008934:Mitogens / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000009:adverse effects / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D007376:Interleukin-2; D008934:Mitogens; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; C028784:phytohemagglutinin-P